Stock 0K5E DRÄGERWERK AG & CO. KGAA
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Drägerwerk AG & Co. KGaA London S.E.

Equities

0K5E

DE0005550636

Market Closed - London S.E.
Other stock markets
 11:30:00 2024-06-21 am EDT 		5-day change 1st Jan Change
49.2 EUR +1.44% Intraday chart for Drägerwerk AG & Co. KGaA -2.96% -6.11%
Jun. 20 Warburg Research raises target for Drägerwerk to 64 euros - 'Buy' DP
Jun. 20 DRAEGERWERK : Warburg Research gives a Buy rating ZD

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's attractive earnings multiples are brought to light by a P/E ratio at 10.17 for the current year.
  • The stock, which is currently worth 2024 to 0.29 times its sales, is clearly overvalued in comparison with peers.
  • The company appears to be poorly valued given its net asset value.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company does not generate enough profits, which is an alarming weak point.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
DRÄGERWERK AG & CO. KGAA Stock Drägerwerk AG & Co. KGaA
-6.11% 939M -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+6.37% 216B
B
DANAHER CORPORATION Stock Danaher Corporation
+10.21% 189B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+28.22% 153B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+34.42% 114B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+0.80% 63.2B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+19.21% 54.78B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+0.13% 48.47B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-4.16% 38.88B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+2.39% 36.14B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DRW3 Stock
  4. 0K5E Stock
  5. Ratings Drägerwerk AG & Co. KGaA